Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulodexide + Conventional Treatment in Stage II PAOD
NCT03370705Phase 3Unknown
- Sponsor
- Alfa Wassermann
- Start
- Jan 2019
- Primary completion
- Dec 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sulodexide in Peripheral Arterial Disease (PAD), sponsored by Alfa Wassermann. Status: unknown.
02
Drugs
sulodexide
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT03370705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03370705.